Valuation: Design Therapeutics, Inc.

Market Cap 901M 781M 732M 667M 1.26B 85.95B 1.28B 8.62B 3.36B 43.02B 3.38B 3.31B 144B P/E 2026 *
-10.5x
P/E 2027 * -8.98x
Enterprise Value 924M 801M 751M 685M 1.29B 88.22B 1.31B 8.84B 3.45B 44.16B 3.47B 3.4B 147B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-1.84%
1 week+4.50%
Current month+18.14%
1 month+3.86%
3 months-7.87%
6 months+42.90%
Current year+53.41%
1 week 13.88
Extreme 13.88
14.9
1 month 11.37
Extreme 11.3669
14.9
Current year 8.23
Extreme 8.23
17.25
1 year 4.68
Extreme 4.68
17.25
3 years 1.94
Extreme 1.94
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
1/2/26 Free

Chief Executive Officer

750,000 1.3166%
1/2/26 Free

Director

45,000 0.0790%
1/2/26 Free

Controller/Auditor

150,000 0.2633%
Change 5-day change 1-year change 3-year change Capi.($)
-1.84%+4.50%+165.50%+87.37% 901M
+1.17%+1.09%+4.03%+15.74% 49.24B
-1.59%+2.12%+460.02%+573.56% 43.3B
-0.85%+7.95%+15.77%+80.09% 40.48B
-0.08%+3.91%+26.96%+9.86% 39.75B
0.00%+3.59%+20.51%+48.00% 32.67B
-3.61%-1.45% - - 16.23B
-2.52%-0.52%+24.35%+118.05% 16.24B
+0.72%+0.31%+4.94%+21.70% 14.04B
-1.09%+5.94%+81.46%+31.15% 13.43B
Average -0.97%+2.52%+89.28%+109.50% 26.63B
Weighted average by Cap. -0.58%+2.72%+96.80%+134.09%

Financials

2026 *2027 *
Net sales - -
Net income -86.04M -74.58M -69.92M -63.75M -120M -8.21B -122M -823M -321M -4.11B -323M -316M -13.71B -115M -99.68M -93.45M -85.2M -160M -10.98B -163M -1.1B -430M -5.49B -432M -422M -18.33B
Net Debt 23.81M 20.64M 19.35M 17.64M 33.2M 2.27B 33.73M 228M 88.94M 1.14B 89.4M 87.46M 3.79B -295M -256M -240M -219M -411M -28.16B -418M -2.82B -1.1B -14.1B -1.11B -1.08B -47.03B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
26-08-13 US$14.39 -1.84% 406,836
26-08-12 US$14.66 +0.27% 465,709
26-08-11 US$14.62 +2.02% 313,443
26-08-10 US$14.33 +2.43% 490,560
26-08-07 US$13.99 +1.60% 418,867
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.39USD
Average target price
21.00USD
Spread / Average Target
+45.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock